News - 16 Feb `23Positive Data From VYNE Therapeutics

New

VYNE Therapeutics Inc. recently announced positive results from the Phase 1a portion of its Phase 1a/b clinical trial evaluating its novel BET inhibitor, VYN201, for vitiligo.

This drug candidate is a locally administered, small molecule, pan-bromodomain and extra-terminal domain (BET) inhibitor. VYN201 was found to upregulate the WNT signaling pathway which is an important mediator of both melanogenesis and melanocyte differentiation and is known to be dysregulated in patients with vitiligo. Library of BET inhibitors is licensed from Tay Therapeutics Ltd,  and protected by a GB patent titled 'Compounds Comprising N-Methyl-2-Pyridone, And Pharmaceutically Acceptable Salts.'

30 healthy volunteers were given single and multiple ascending doses of VYN201 ointment in five dose cohorts over two weeks, with a one-week safety follow-up visit. The doses included 0.025%, 0.1%, 0.5%, 1.0% and 2.0%, and it was generally well-tolerated with no clinically relevant adverse events from all dose cohorts.

In addition to the safety assessment, exploratory efficacy of VYN201 in non-segmental vitiligo patients will be evaluated, including pharmacodynamic biomarkers and photography.

These positive results have also caused VYNE Therapeutics shares to increase 8%.

📌 Vitiligo Drug Pipeline Analysis and Market Insights

 



      FAQOther Questions

      • How long does it take to treat vitiligo?

        Vitiligo, a condition characterized by the loss of skin pigment, can be unpredictable in both progression and treatment. The time it takes to treat vitiligo varies significantly...

      • Is there a traditional medicine to treat vitiligo?

        Traditional remedies can play a supportive role in managing chronic, metabolic, and stress-related conditions—particularly early in the disease process, before significant tissu...

      • Can chemicals cause vitiligo?

        Certain chemicals can trigger vitiligo, leading to a condition known as chemical-induced vitiligo. While clinically and histologically indistinguishable from other types of viti...